Toyota|$17.75 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.81 (¥4,271)-1.13%▼ (in JPY terms)
SoftBank|$20.60 (¥3,281)-3.95%▼ (in JPY terms)
MUFG|$20.63 (¥3,287)-3.75%▼ (in JPY terms)
Keyence|$455.15 (¥72,510)-1.28%▼ (in JPY terms)
Nintendo|$56.03 (¥8,926)+0.36%▲ (in JPY terms)
NTT|$1.07 (¥170)+0.77%▲ (in JPY terms)
Takeda|$43.51 (¥6,931)-0.09%▼ (in JPY terms)
Tokyo Electron|$54.34 (¥8,657)-1.56%▼ (in JPY terms)
Recruit|$114.21 (¥18,195)+5.02%▲ (in JPY terms)
ITOCHU|$14.65 (¥2,334)-2.59%▼ (in JPY terms)
Honda|$11.28 (¥1,797)-2.10%▼ (in JPY terms)
Shin-Etsu|$34.99 (¥5,574)-0.85%▼ (in JPY terms)
Tokio Marine|$3.67 (¥584)-2.23%▼ (in JPY terms)
Fast Retailing|$529.78 (¥84,400)+0.79%▲ (in JPY terms)
Toyota|$17.75 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.81 (¥4,271)-1.13%▼ (in JPY terms)
SoftBank|$20.60 (¥3,281)-3.95%▼ (in JPY terms)
MUFG|$20.63 (¥3,287)-3.75%▼ (in JPY terms)
Keyence|$455.15 (¥72,510)-1.28%▼ (in JPY terms)
Nintendo|$56.03 (¥8,926)+0.36%▲ (in JPY terms)
NTT|$1.07 (¥170)+0.77%▲ (in JPY terms)
Takeda|$43.51 (¥6,931)-0.09%▼ (in JPY terms)
Tokyo Electron|$54.34 (¥8,657)-1.56%▼ (in JPY terms)
Recruit|$114.21 (¥18,195)+5.02%▲ (in JPY terms)
ITOCHU|$14.65 (¥2,334)-2.59%▼ (in JPY terms)
Honda|$11.28 (¥1,797)-2.10%▼ (in JPY terms)
Shin-Etsu|$34.99 (¥5,574)-0.85%▼ (in JPY terms)
Tokio Marine|$3.67 (¥584)-2.23%▼ (in JPY terms)
Fast Retailing|$529.78 (¥84,400)+0.79%▲ (in JPY terms)

Meiji Holdings Co.,Ltd. (2269)

TSE 2269 · Food

Meiji Holdings Co.,Ltd.

明治ホールディングス株式会社
$28.95 (¥4,612)
+390.0 (+9.24%)in JPY terms
Delayed quote · Yahoo Finance
🏢 Industry: Food
🌐 ISIN: JP3918000005
📊 TSE: 2269
Company Overview

Meiji Holdings is one of Japan's most recognized consumer food and pharmaceutical companies. Its food division produces dairy products, confectionery, nutritional supplements, and sports nutrition products under the widely trusted Meiji brand. The pharmaceutical arm, Meiji Seika Pharma, focuses on antibiotics and generic drugs. The company's dual business structure provides revenue diversification, while its strong brand recognition in Japan supports consistent consumer demand across its product portfolio.

For international investors, Meiji Holdings presents a diversified food and pharmaceutical profile, combining consumer staple revenues from dairy and confectionery with growing pharmaceutical operations. The company's well-recognized brands and established distribution network in Japan provide earnings stability, while the pharmaceutical division offers exposure to Japan's healthcare market.

Recent Press Releases
2026-11-182026-11-17 Meiji Holdings Co.,Ltd. “Announcement Regarding Investment in Arcturus Therapeutics, Inc. (USA) to Expand Collaboration in mRNA Vaccines and Pharmaceuticals (697KB) November 17, 2026 Pharmaceutical IR.”2026-11-182026-11-17 Meiji Holdings Co.,Ltd. “Continuous consumption of high-cacao chocolate alone or in combination with milk protein beverages may lead to the maintenance and increase of muscle-related indicators in the elderly. A difference in skeletal muscle mass was observed in the group that consumed milk protein beverages compared to the non-consumption group from 8 weeks onward. This is a collaborative research project between Sapporo City, Hokkaido Information University, and Meiji. The paper was published in 'BMC Nutrition' on August 3rd and presented at ICPH & ICoFF 2026 on October 15th. Food product designation dated November 17th, 2026.”2026-11-172026-11-16 Meiji Holdings Co.,Ltd. “The series has surpassed 150 million units shipped! A rich, limited-edition winter flavor is now available from the popular "Meiji Bulgaria Frozen Yogurt Dessert" line. "Meiji Bulgaria Frozen Yogurt Dessert <Winter>" will be released on November 23rd / available nationwide from November 16th, 2026.”2026-11-172026-11-16 Meiji Holdings Co.,Ltd. “Announcement of approval for an additional indication for the photodynamic therapy agent "Resaphyrin® 100mg for injection" for cervical intraepithelial neoplasia (658KB) November 16, 2026. Pharmaceutical product.”2026-11-142026-11-13 Meiji Holdings Co.,Ltd. “The video explaining the financial results for the second quarter (interim period) of the fiscal year ending March 2027 was posted on November 13, 2026, in the IR Corporate section.”2026-11-142026-11-13 Meiji Holdings Co.,Ltd. “The financial results presentation materials (with script) for the second quarter (interim period) of the fiscal year ending March 2027 were posted on November 13, 2026, in the IR Corporate section.”2026-11-132026-11-12 Meiji Holdings Co.,Ltd. “The financial results presentation materials for the second quarter (interim period) of the fiscal year ending March 2027 were posted on November 12, 2026, in the IR Corporate section.”2026-11-132026-11-12 Meiji Holdings Co.,Ltd. “Financial Results for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese Standards] (Consolidated) (959KB) November 12, 2026 IR Corporate.”2026-11-132026-11-12 Meiji Holdings Co.,Ltd. “Notice Regarding Decisions on Matters Concerning the Acquisition of Treasury Stock (127KB) November 12, 2026 IR Corporate.”2026-11-062026-11-05 Meiji Holdings Co.,Ltd. “Meiji Seika Pharma, Regeneflo, and Kyoto University's Center for iPS Cell Research and Application (AIST) continue and promote their tripartite collaborative research – aiming to create new treatments utilizing iPS cell-derived human disease models (406KB) November 5, 2026. Pharmaceuticals.”
Key Data
52W High
$29.11 (¥4,638)
52W Low
$19.63 (¥3,128)
TSE Code
2269
ISIN
JP3918000005